Navigation Links
Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Date:8/8/2008

e cancer in tumor bearing mouse models with intravenous

PEGPH20 in combination with the chemotherapeutic drugs, docetaxel

(Taxotere(R)) or liposomal doxorubicin (Doxil(R)) resulted in a

substantial increase in anti-tumor activity. The docetaxel combination

treatment demonstrated significantly enhanced survival compared to

treatment with the chemotherapeutic agent alone. The effects of PEGPH20

were selective to prostate tumors producing hyaluronan, consistent with

the selective reduction of tumor interstitial fluid pressure. Treatment

with PEGPH20 was well tolerated without significant increases in

neutropenia (depletion of neutrophils, a type of white blood cell)

compared to chemotherapy alone.

-- New pre-clinical findings on the controlled modification of the

extracellular matrix with HTI-501 at the European Society for

Dermatological Research and Japanese Society for Investigative

Dermatology. HTI-501, a new recombinant human lysosomal proteinase

that could provide an effective dermatologic treatment by targeting and

degrading the fibrous components of the extracellular matrix in a

highly controlled fashion. This new molecular entity is being explored

as a potential solution for medical, as well as aesthetic, dermatology

indications for which surgery may be impractical, such as cellulite and

certain forms of scarring. HTI-501 works by a process called enzymatic

subscision, which involves degradation of fibrous septae (or cords) in

a controllable and predictable manner to release skin tissue from the

fibrous cords and smooth out the surface contour. It could be

especially beneficial in aesthetic dermatology indications.

Second Quarter 2008 Financial Results

-- Net loss for the second quarter of 2008 was $11.0 million, or $0.14 per


'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
2. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
3. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
4. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
5. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
8. Halozyme Therapeutics Amends Stockholder Rights Plan
9. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
10. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
11. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... According to the new Market Research ... Media), by Application (Biobanking, Regenerative Medicine, Drug Discovery), by Geography ... , Asia-Pacific , Rest of the World) ... market was valued at $247.7 million in 2014, which is ... a CAGR of 18.2% between 2014 and 2019. ...
(Date:7/27/2015)... July 27, 2015 Junto Health, a company ... information and develop new technology solutions, today announced the ... (SPG), a leader in health care policy consulting. Working ... in a collaborative innovation process while, at the same ... in public policy, health care finance and the delivery ...
(Date:7/27/2015)... ... , ... Visual Assay was named as a finalist for the 53rd Annual ... services of the past year. More than 70 judges selected the finalists, including ... announced at the 2015 R&D 100 Awards Dinner on November 13 at Caesars Palace ...
(Date:7/25/2015)... , ... July 25, 2015 , ... ... its refractometer series. It precisely checks and adjusts the surface temperature of the ... , In the pharmaceutical industry, data traceability and documentation are key requirements. It ...
Breaking Biology Technology:Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2It’s T-Time for Refractometers: On-site Temperature Check Now Available 2
... Mersana, a cancer,therapeutics company, announced today that Timothy ... Officer., "We are thrilled that Tim is now ... President and CEO at Mersana. "His extensive leadership in,oncology ... an,ideal match for Mersana. In addition to the important ...
... CuraGen Corporation,(Nasdaq: CRGN ) announced today that ... present at the BIO CEO & Investor Conference,on Wednesday, ... Access to a live webcast of the presentation ... the webcast will be accessible,beginning one hour after the ...
... at 2008 BIO CEO & Investor conference at the Waldorf-Astoria ... on Tuesday, February 12 at 1:15 PM (Eastern), NEW ... A. Bianco, M.D., President and CEO of Cell,Therapeutics, Inc. (CTI) ... Company,s sales and marketing strategy intended to grow Zevalin(R),(Ibritumomab Tiuxetan) ...
Cached Biology Technology:Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D. 2Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 2Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 3Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 4Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008 5
(Date:7/23/2015)... July 23, 2015 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its second quarter ended June 30, ... 2015 was $4.5 million, a decrease of 33% compared to ... in the second quarter of 2015 was $0.3 million, or ... $0.04 per diluted share, in the same period a year ...
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/13/2015)... July 13, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced sampling of ClearPad ® ... driver integration (TDDI) product targeting smartphones and tablets. ... combine Synaptics , best-in-class touch controller IP ... technology developed in the company,s Japan Design Center. ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... Irvine, Calif., Nov. 21, 2011 UC Irvine and Italian ... of anandamide a natural, marijuana-like chemical in the body ... Louise Turner Arnold Chair in the Neurosciences, the team identified ... sites within the cell where enzymes break it down. They ...
... Log and lumber exports from Washington, Oregon, northern California, and ... the total exports of 2010 according to the U.S. Forest ... shipments to China are the main driver of the hike ... Xiaoping Zhou, a research economist with the station. "The log ...
... with 43 of the companies honored by Thomson Reuters ... a record year of expansion, fueled by businesses, increased ... "The organizations that continue to surge ahead ... innovate," said Andy Zynga, Chief Executive Officer of NineSigma, ...
Cached Biology News:UCI-led team finds new way to boost potency of marijuana-like chemical in body 2West coast log, lumber exports in first 9 months of 2011 surpass 2010 totals 2West coast log, lumber exports in first 9 months of 2011 surpass 2010 totals 3Surging Demand for Innovation Services Leads to Record Expansion for NineSigma 2Surging Demand for Innovation Services Leads to Record Expansion for NineSigma 3
ID clarifier: Without ethidium bromide...
... / 3T3 cells were cultured in DMEM with ... phase of growth. In order to keep ... fixed in acetone-methanol. The cells are arrayed ... with each wells surface specifically treated to enhance ...
... Application: Acridine orange has been used as ... agarose and polyacrylamide gels. Acridine orange at ... purified DNA in gels with a sensitivity ... also been used extensively for cell staining ...
... vector can be induced prior to DNA ... the stability of single-copy BACs with the ... cloning vectors. The kits provide the linearized ... size screening system) necessary to create a ...
Biology Products: